• Aushon BioSystems (Billerica, Massachusetts) reported the expansion of its microarray service line to include offerings dedicated to reverse phase arrays (RPA). Unlike forward phase arrays in which antibodies or recombinant proteins are printed onto substrates, RPAs are created by depositing the samples to be analyzed, such as cell/tissues lysates or blood plasma, directly onto substrates. These arrays are particularly useful for high throughput analysis of protein levels and post-translational modifications, which in turn are key in biomarker identification and drug discovery programs. Aushon BioSystems provides microarray instrumentation and services.

• Biotronik (Berlin) reported the launch of the Lumax 540 series, which includes implantable cardioverter defibrillators (ICDs) and a cardiac resynchronization therapy defibrillator (CRT-D). Together with Biotronik Home Monitoring, this enables continuous automatic daily data transmission of the patient's cardiovascular status. The information is available to the physicians online allowing them to continuously check their patients' cardiac and device status. The Lumax 540 devices offer the combination of advanced tachycardia therapy management, diagnostic capabilities and remote monitoring technologies that support physicians in creating efficient care pathways for their patients with cardiac devices and further improve patient care. Biotronik makes wireless monitoring technology.

• Caris Diagnostics (Irving, Texas) said it is offering KRAS mutation analysis, designed to provide information on which colon cancer patients are most likely to respond to cetuximab (Erbitux), co-marketed by ImClone and Bristol-Myers Squibb, or panitumumab (Vectibix), developed by Amgen. This assay, which can be performed on biopsies taken for the initial cancer diagnosis, identifies those patients who have somatic mutations in KRAS, which is associated with a lack of response to Erbitux or Vectibix. This prognostic information has been validated in a number of retrospective studies and will help better suggest which patients are most likely not going to respond to Erbitux or Vectibix. Caris Diagnostics provides diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing.

• Fujifilm Medical Systems USA (Stamford, Connecticut) introduced the Breast Imaging Diagnostic Workstation (BIDW). Available for any U.S. facility that has implemented Full Field Digital Mammography (FFDM), the BIDW is being introduced specifically to complement Fujifilm's Computed Radiography for Mammography (FCRm) solution and provide better workstation interpretation capabilities for facilities that may use another vendor's PACS. Delivering full Synapse PACS functionality, this new standalone workstation is designed to be a supplement to any facility's existing PACS, and meet the market need for more clinically and operationally advanced systems to support breast imaging. Fujifilm Medical Systems USA is a provider of diagnostic imaging products and network systems to meet the needs of healthcare facilities.

• IMIX Americas (Sterling, Virginia) said it has expanded its product line with the addition of an industry-leading 17" by 17" field of view detector. The detector accommodates most patient sizes and is ideal for imaging applications requiring full anatomical coverage. The company said the enhanced detector features the same high image quality and reliability as the 16" model. IMIX makes digital radiography systems.